United Therapeutics (NASDAQ:UTHR) CEO Sells $1,840,000.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $460.00, for a total value of $1,840,000.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $59,800. This represents a 96.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Up 0.9%

United Therapeutics stock opened at $466.40 on Friday. The company has a market cap of $20.08 billion, a PE ratio of 17.67, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $479.50. The company’s 50-day moving average is $432.38 and its two-hundred day moving average is $349.68.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the previous year, the firm posted $6.39 earnings per share. United Therapeutics’s revenue for the quarter was up 6.8% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on UTHR. Cantor Fitzgerald lifted their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. HC Wainwright upped their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $503.90.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Envestnet Asset Management Inc. lifted its position in shares of United Therapeutics by 18.1% in the first quarter. Envestnet Asset Management Inc. now owns 71,909 shares of the biotechnology company’s stock worth $22,167,000 after purchasing an additional 11,029 shares in the last quarter. Alps Advisors Inc. increased its stake in United Therapeutics by 10.4% in the 1st quarter. Alps Advisors Inc. now owns 1,116 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 105 shares during the last quarter. Victory Capital Management Inc. lifted its position in United Therapeutics by 27.4% during the 1st quarter. Victory Capital Management Inc. now owns 246,359 shares of the biotechnology company’s stock worth $75,945,000 after buying an additional 52,951 shares in the last quarter. Tributary Capital Management LLC lifted its position in United Therapeutics by 50.0% during the 1st quarter. Tributary Capital Management LLC now owns 1,125 shares of the biotechnology company’s stock worth $347,000 after buying an additional 375 shares in the last quarter. Finally, Archer Investment Corp boosted its stake in shares of United Therapeutics by 41.1% during the 1st quarter. Archer Investment Corp now owns 1,115 shares of the biotechnology company’s stock worth $344,000 after buying an additional 325 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.